Top

Irish Journal of Medical Science (1971 -)

Published in:

01-08-2020 | Coronary Heart Disease | Original Article

Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation

Authors: Jiayu Zhao, Xun Wang, Haiyan Wang, Ying Zhao, Xianghua Fu

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2020

Abstract

Background

This study aimed to investigate the occurrence and predictive factors of restenosis in coronary heart disease (CHD) patients underwent percutaneous coronary intervention (PCI) with sirolimus-eluting stent (SES).

Methods

Demographic data, clinical features, and laboratory tests of 398 CHD patients underwent PCI with SES were retrospectively reviewed. Coronary angiography was performed to evaluate coronary stenosis before PCI and in-stent restenosis at 1-year follow-up.

Results

There were 37 (9.3%) patients suffered restenosis, but 361 (90.7%) patients did not develop restenosis at 1-year follow-up. Demographic characteristic (age), cardiovascular risk factors (hypertension and hyperuricemia), biochemical indexes (fasting blood-glucose, total cholesterol, low density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (HsCRP)), cardiac function index (cardiac troponin I), lesion features (multivessel artery lesions, target lesion at left circumflex artery (LCX), two target lesions and length of target lesion), and operation procedure (length of stent) were correlated with higher restenosis risk. Moreover, age, hypertension, diabetes mellitus, LDL-C, HsCRP, and target lesion at LCX were independent predictive factors for raised restenosis risk. Based on these independent predictive factors, we established a restenosis risk prediction model, and receiver-operating characteristic curves displayed that this model exhibited an excellent predictive value for higher restenosis risk (areas under the curve 0.953 (95% CI 0.926–0.981)).

Conclusion

Our findings provide a new insight into the prediction for restenosis in CHD patients underwent PCI with SES.

Piccolo R, Giustino G, Mehran R, Windecker S (2015) Stable coronary artery disease: revascularisation and invasive strategies. Lancet 386(9994):702–713CrossRef

Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A (2016) Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 4(13):256CrossRef

Zheng X, Zheng Y, Ma J, Zhang M, Zhang Y, Liu X, Chen L, Yang Q, Sun Y, Wu J, Yu B (2019) Effect of exercise-based cardiac rehabilitation on anxiety and depression in patients with myocardial infarction: a systematic review and meta-analysis. Heart Lung 48(1):1–7CrossRef

Beatty AL, Doll JA, Schopfer DW, Maynard C, Plomondon ME, Shen H, Whooley MA (2018) Cardiac rehabilitation participation and mortality after percutaneous coronary intervention: insights from the veterans affairs clinical assessment, reporting, and tracking program. J Am Heart Assoc 7(19):e010010CrossRef

Tian Y, Deng P, Li B, Wang J, Li J, Huang Y, Zheng Y (2019) Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance. Rev Cardiovasc Med 20(1):27–33CrossRef

Nazneen F, Herzog G, Arrigan DW, Caplice N, Benvenuto P, Galvin P, Thompson M (2012) Surface chemical and physical modification in stent technology for the treatment of coronary artery disease. J Biomed Mater Res B Appl Biomater 100(7):1989–2014CrossRef

Arafat M, Fouladian P, Blencowe A, Albrecht H, Song Y, Garg S (2019) Drug-eluting non-vascular stents for localised drug targeting in obstructive gastrointestinal cancers. J Control Release 308:209–231CrossRef

Zahn R, Hamm CW, Schneider S, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J, German Cypher Stent R (2007) The Sirolimus-eluting coronary stent in daily routine practice in Germany: trends in indications over the years. Results from the prospective multi-centre German Cypher Stent registry. Clin Res Cardiol 96(8):548–556CrossRef

Mazin I, Paul G, Asher E (2019) Neoatherosclerosis - from basic concept to clinical implication. Thromb Res 178:12–16CrossRef

10.

Ray GM, Nawarskas JJ, Frishman WH (2006) The paclitaxel-eluting stent in percutaneous coronary intervention: part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions. Cardiol Rev 14(3):143–150CrossRef

11.

Yates DJ, Savage ML, Walters DL, Raffel OC (2016) Retrospective study of first-generation drug-eluting stents, second-generation drug-eluting stents and non-drug eluting stent methods in the treatment of native vessel in-stent restenosis in real-world clinical practice. Heart Lung Circ 25(4):342–351CrossRef

12.

Farooq V, Gogas BD, Serruys PW (2011) Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv 4(2):195–205CrossRef

13.

Xiu WJ, Yang HT, Zheng YY, Ma YT, Xie X (2018) Drug-eluting balloons versus second-generation drug-eluting stents for treating in-stent restenosis in coronary heart disease after PCI: a meta-analysis. Cardiol Res Pract 2018:7658145CrossRef

14.

Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A (2006) Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113(19):2293–2300CrossRef

15.

Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, Chan SP, Xu HF, Yang XJ (2015) Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis 26(1):5–10CrossRef

16.

Wu Y, Fu X (2019) Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. J Clin Lab Anal 33(2):e22666CrossRef

17.

Qian H, Luo Z, Xiao C, Chen J, Li D, Xu H, He P, Zhou X, Zhang T, Min X (2018) Red cell distribution width in coronary heart disease: prediction of restenosis and its relationship with inflammatory markers and lipids. Postgrad Med J 94(1115):489–494CrossRef

18.

Obata JE, Nakamura T, Kitta Y, Saito Y, Sano K, Fujioka D, Kawabata K, Kugiyama K (2013) In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter. Catheter Cardiovasc Interv 82(6):E777–E787CrossRef

19.

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, American College of Cardiology F, American Heart Association Task Force on Practice G, Society for Cardiovascular A, Interventions (2013) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 82(4):E266–E355PubMed

20.

Bruining N, Sabate M, de Feyter PJ, Kay IP, Ligthart J, Disco C, Kutryk MJ, Roelandt JR, Serruys PW (1999) Quantitative measurements of in-stent restenosis: a comparison between quantitative coronary ultrasound and quantitative coronary angiography. Catheter Cardiovasc Interv 48(2):133–142CrossRef

21.

Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, Serruys PW (1993) Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Catheter Cardiovasc Diagn 30(2):104–114CrossRef

22.

Siontis GC, Piccolo R, Praz F, Valgimigli M, Raber L, Mavridis D, Juni P, Windecker S (2016) Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis. JACC Cardiovasc Interv 9(13):1324–1334CrossRef

23.

Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27(7):1500–1510CrossRef

24.

Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R (2011) Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 4(1):38–46CrossRef

25.

Park HJ, Kim HY, Lee JM, Choi YS, Park CS, Kim DB, Her SH, Koh YS, Park MW, Kwon BJ, Kim PJ, Chang K, Chung WS, Seung KB (2012) Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CAtholic Total Occlusion Study (CATOS) trial. Circ J 76(4):868–875CrossRef

26.

Ge L, Iakovou I, Cosgrave J, Chieffo A, Montorfano M, Michev I, Airoldi F, Carlino M, Melzi G, Sangiorgi GM, Corvaja N, Colombo A (2005) Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 26(11):1056–1062CrossRef

27.

Chatani K, Muramatsu T, Tsukahara R, Ito Y, Ishimori H, Hirano K, Nakano M, Yamawaki M, Araki M, Sakurai M, Iuchi K, Nozawa T, Inoue H (2009) Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous coronary intervention for SES restenosis. J Interv Cardiol 22(4):354–361CrossRef

28.

Ishii H, Toriyama T, Aoyama T, Takahashi H, Amano T, Hayashi M, Tanaka M, Kawamura Y, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T (2009) Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. Circ Cardiovasc Interv 2(6):513–518CrossRef

29.

Asamasu-Sato S, Mita M, Ogawa R, Isaka M, Saito M (2007) Analysis of clinical factors that influence re-stenosis after percutaneous coronary stenting. Yakugaku Zasshi 127(8):1309–1315CrossRef

30.

Mohan S, Dhall A (2010) A comparative study of restenosis rates in bare metal and drug-eluting stents. Int J Angiol 19(2):e66–e72CrossRef

31.

Aronson D (2002) Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 59(3):297–301CrossRef

32.

Ping S, Liu S, Zhou Y, Li Z, Li Y, Liu K, Bardeesi AS, Wang L, Chen J, Deng L, Wang J, Wang H, Chen D, Zhang Z, Sheng P, Li C (2017) Protein disulfide isomerase-mediated apoptosis and proliferation of vascular smooth muscle cells induced by mechanical stress and advanced glycosylation end products result in diabetic mouse vein graft atherosclerosis. Cell Death Dis 8(5):e2818CrossRef

33.

Li C, Shen Y, Xu R, Dai Y, Chang S, Lu H, Dong Z, Deng J, Qian J, Ge J (2018) Evaluation of Preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions. Angiology:3319717752245

34.

Li JJ, Yan HB, Xiang XP, Qin XW, Zhang CY (2009) Comparison of changes in early inflammatory markers between sirolimus- and paclitaxel-eluting stent implantation. Cardiovasc Drugs Ther 23(2):137–143CrossRef

35.

Nakazawa KR, Wengerter SP, Power JR, Lookstein RA, Tadros RO, Ting W, Faries PL, Vouyouka AG (2017) Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation. J Vasc Surg 66(1):151–159CrossRef

36.

Naganuma T, Chieffo A, Basavarajaiah S, Takagi K, Costopoulos C, Latib A, Carlino M, Montorfano M, Bernelli C, Nakamura S, Colombo A (2013) Single-stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery. Catheter Cardiovasc Interv 82(5):757–764CrossRef

Title: Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation
Authors: Jiayu Zhao
Xun Wang
Haiyan Wang
Ying Zhao
Xianghua Fu
Publication date: 01-08-2020
Publisher: Springer London
Keywords: Coronary Heart Disease
Hypertension
Diabetes
Hypertension
Published in: Irish Journal of Medical Science (1971 -) / Issue 3/2020
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-020-02176-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Statistical analysis of fat and muscle mass in osteoporosis in elderly population using total body DXA scans

Does membrane sweep work? Assessing obstetric outcomes and patient perception of cervical membrane sweeping at term in an Irish obstetric population: a prospective multi-centre cohort study

Impact of atrial fibrillation on frailty and functionality in older adults

Risk factors of systematic biliary complications in patients with gallbladder stones

Retraction Note: Obturator nerve block transurethral surgery for bladder cancer: comparison of inguinal and intravesical approaches: prospective randomized trial

“Rapid sequence induction”—an anaesthesiology boot camp

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials